The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,102,760 in first-year total cost, median $389,071.
Most frequent study sections
- Special Emphasis Panel[ZTR1 NTU-2 (01)]1
- Special Emphasis Panel[ZTR1 NTU-2 (02)]1
- Special Emphasis Panel[ZTR1 NTU-5 (01)]1
Most frequent institutions
- CMTX BIOTECH, INC.1
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
- VANDERBILT UNIVERSITY MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Network-driven drug repurposing in cardiovascular disease: NDRA clinical trial planning1U34TR003594-01 | GIANNARELLI, CHIARA | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $398,689 | ZTR1 |
| 2021 | Repurposing Incyclinide for the Treatment of Hospitalized COVID-19 Patients1U34TR003593-01 | SCADUTO, JOSEPH | CMTX BIOTECH, INC., NY | $315,000 | ZTR1 |
| 2020 | Repurposing Montelukast for Cardiac Surgery-Associated Acute Kidney Injury1U34TR003298-01 | BILLINGS, FREDERIC TREMAINE | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $389,071 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.